Cathepsin L Inhibitor
(Synonyms: SB 412515; Z-FY-CHO) 目录号 : GC18498A potent and selective cathepsin L inhibitor
Cas No.:167498-29-5
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cathepsin L inhibitor is a potent inhibitor of cathepsin L (IC50 = 0.85 nM). [1] It is selective for cathepsin L over calpain II and cathepsin B (IC50s = 184, and 85.1 nM, respectively). It is trypanocidal with an ED50 value of 45 nM against T. brucei that is well below the ED50 value of 21,500 nM for human HL-60 cells. [2] Cathepsin L inhibitor completely suppresses osteoclastic pit formation on femur slices isolated from bovine cortical bone at a concentration of 1 μg/ml., [1][3] In vivo, cathepsin L inhibitor (2.5-10 mg/kg) inhibits bone loss in a mouse model of osteoporosis in a dose-dependent manner.
Reference:
[1]. Woo, J.-T., Sigeizumi, S., Yamaguchi, K., et al. Peptidyl aldehyde derivatives as potent and selective inhibitors of cathepsin L. Bioorganic Med. Chem. Lett. 5(14), 1501-1504 (1995).
[2]. Nkemngu, N.J., Grande, R., Hansell, E., et al. Improved trypanocidal activities of cathepsin L inhibitors. Int. J. Antimicrob. Agents 22(2), 155-159 (2003).
[3]. Woo, J.-T., Yamaguchi, K., Hayama, T., et al. Suppressive effect of N-(benzyloxycarbonyl)-L-phenylalanyl-L-tyrosinal on bone resorption in vitro and in vivo. Eur. J. Pharmacol. 300(1-2), 131-135 (1996).
Cas No. | 167498-29-5 | SDF | |
别名 | SB 412515; Z-FY-CHO | ||
化学名 | N-[(1S)-2-[[(1S)-1-formyl-2-(4-hydroxyphenyl)ethyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-carbamic acid, phenylmethyl ester | ||
Canonical SMILES | OC1=CC=C(C[C@@H](C=O)NC([C@H](CC2=CC=CC=C2)NC(OCC3=CC=CC=C3)=O)=O)C=C1 | ||
分子式 | C26H26N2O5 | 分子量 | 446.5 |
溶解度 | 20 mg/ml in DMSO, 20 mg/ml in DMF, 2 mg/ml in Ethanol | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.2396 mL | 11.1982 mL | 22.3964 mL |
5 mM | 0.4479 mL | 2.2396 mL | 4.4793 mL |
10 mM | 0.224 mL | 1.1198 mL | 2.2396 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。